# STELLAR-311 (NCT06943755)

> Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06943755
- Phase: PHASE2, PHASE3
- Status: RECRUITING
- Sponsor: Exelixis
- Conditions: Pancreatic Neuroendocrine Tumor (pNET); Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Interventions: Zanzalintinib; Everolimus
- Enrollment: 440
- Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)

## Commentary we found

- YouTube: 5
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=stellar-311-nct06943755